In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae

John H. Rex, John E. Bennett, John I. Gallin, Harry L. Malech, Ellen S. DeCarlo, David A. Melnick

Research output: Contribution to journalArticle

Abstract

During the recently completed double-blind, placebo-controlled, randomized trial of recombinant interferon-γ (rIFN-γ) therapy in chronic granulomatous disease (CGD), a metabolic assay of neutrophil damage to Aspergillus fumigatus hyphae was used to monitor neutrophil function before and during therapy. In this assay, 5 × 104 conidia that had germinated into hyphae were exposed to 5 × 105, 15 × 105, or 50 × 105 CGD neutrophils. By analysis of variance, neutrophils from patients on rIFN-γ were found to produce significantly more damage to hyphae than those from the placebo group (P < .01). In subgroup analysis, this effect was best seen in the hyphae exposed to 50 × 105 CGD neutrophils, where neutrophils from patients receiving rIFN-γ produced significantly more damage to the hyphae than those from the placebo group (P < .05). In vivo rIFN-γ therapy improves the ability of CGD neutrophils to damage Aspergillus fumigatus hyphae in an in vitro assay.

Original languageEnglish (US)
Pages (from-to)849-852
Number of pages4
JournalJournal of Infectious Diseases
Volume163
Issue number4
DOIs
StatePublished - Apr 1991

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae'. Together they form a unique fingerprint.

  • Cite this